Equities

Dare Bioscience Inc

DARE:NAQ

Dare Bioscience Inc

Actions
  • Price (USD)3.23
  • Today's Change0.05 / 1.57%
  • Shares traded52.18k
  • 1 Year change-20.55%
  • Beta1.2991
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.

  • Revenue in USD (TTM)1.88m
  • Net income in USD-3.60m
  • Incorporated2005
  • Employees23.00
  • Location
    Dare Bioscience Inc3655 Nobel Dr Ste 260SAN DIEGO 92122-1050United StatesUSA
  • Phone+1 (858) 926-7655
  • Fax+1 (302) 636-5454
  • Websitehttps://www.darebioscience.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DH Enchantment Inc100.00-173.19k19.54m1.00------195,396.80-0.0002-0.00020.00-0.00120.04380.1493--100.00-7,579.43------0.00---173,190.00--0.0029-14.85-----95.43--59.53------
Cyclo Therapeutics Inc870.72k-24.80m20.34m8.00------23.36-0.9232-0.92320.0322-0.46830.16050.3423.54108,840.00-457.10-132.22---215.1791.2490.37-2,848.18-1,114.040.1614-------21.761.25-29.81---3.95--
China Health Industries Holdings, Inc.95.95k-1.36m21.30m32.00------221.99-0.0208-0.02080.0015-0.03660.00370.503520.572,998.44-5.183.04-6.893.66-5.3469.55-1,419.4928.610.0377--1.76--41,225.93-55.72-15.49------
Nexgel Inc6.73m-3.53m22.34m19.00--4.78--3.32-0.5815-0.58151.100.69020.65583.216.56354,105.30-37.28-44.61-51.10-56.1931.615.02-56.85-180.980.9291--0.2235--99.6613.0633.48------
Polypid Ltd0.00-26.86m23.74m59.00--11.00-----7.48-7.480.000.31720.00----0.00-132.55-76.92-222.42-89.61-----------25.480.7813------39.67---42.34--
BioXcel Therapeutics Inc2.28m-71.00m23.96m74.00------10.53-2.15-2.150.0637-2.020.03051.146.1730,756.76-95.08-74.57-168.28-84.0610.98---3,119.33-32,300.741.81-6.545.55--268.00---8.02---43.26--
Natural Alternatives International, Inc.112.98m-8.50m27.40m296.00--0.3417--0.2425-1.45-1.4519.1912.940.70284.358.25381,679.10-5.292.33-6.042.805.3014.24-7.532.061.50-9.350.15360.00-26.11-3.82-386.16---10.75--
Dare Bioscience Inc1.88m-3.60m27.65m23.00------14.69-0.5276-0.52760.2303-0.17370.0873--2.2881,796.52-16.72-109.51-199.47-246.263.50---191.61-1,104.55---------71.92--2.54--121.37--
KALA BIO Inc0.00-38.96m29.63m43.00--4.32-----12.47-12.470.001.490.00----0.00-67.64-57.83-96.17-69.32--57.06---1,553.61---11.210.8367---100.00--5.85---17.31--
Opus Genetics Inc8.38m-27.19m30.81m14.00--0.7485--3.68-1.09-1.090.33691.310.1772--1.14598,642.90-57.50-58.31-64.30-65.94-----324.45-137.92----0.00---52.20---155.83------
ImmuCell Corp23.84m-3.81m32.08m74.00--1.20--1.35-0.4856-0.48563.032.990.53572.3511.43301,746.80-8.56-5.16-9.39-5.5326.7140.04-15.99-12.641.44-6.210.2922---5.909.72-131.56---1.39--
Tonix Pharmaceuticals Holding Corp11.29m-135.25m35.51m103.00--0.3985--3.14-52.81-52.810.64770.47680.09640.82914.05109,621.40-115.46-59.46-134.34-65.9220.74---1,197.86-5,126.732.78--0.0972------0.1874--320.57--
Akari Therapeutics PLC (ADR)0.00-20.13m36.40m9.00---------2.98-2.980.00-0.30490.00----0.00-307.64-149.95---435.18-----------378.19--------43.61------
Incannex Healthcare Inc86.00k-23.15m36.87m9.00--5.59--428.76-1.40-1.400.00520.3738------9,555.56---130.12---148.24-----26,922.09-3,421.98----0.00----61.0362.18--73.79--
Data as of Nov 21 2024. Currency figures normalised to Dare Bioscience Inc's reporting currency: US Dollar USD

Institutional shareholders

7.47%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2024284.79k3.33%
AMH Equity Ltd.as of 30 Sep 2024100.00k1.17%
Geode Capital Management LLCas of 30 Sep 202489.06k1.04%
Renaissance Technologies LLCas of 30 Sep 202464.40k0.75%
SSgA Funds Management, Inc.as of 30 Sep 202423.52k0.28%
Commonwealth Equity Services LLCas of 30 Sep 202417.49k0.21%
BlackRock Fund Advisorsas of 30 Sep 202416.97k0.20%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 202415.46k0.18%
Advisory Services Network LLCas of 30 Sep 202415.00k0.18%
Founders Financial Securities LLCas of 30 Sep 202411.59k0.14%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.